Samsung Biologics Inks Manufacturing Deal with GreenLight | Be Korea-savvy

Samsung Biologics Inks Manufacturing Deal with GreenLight


This undated photo, provided by Samsung Biologics, shows one of its three plants in Songdo, west of Incheon, South Korea.

This undated photo, provided by Samsung Biologics, shows one of its three plants in Songdo, west of Incheon, South Korea.

SEOUL, Nov. 25 (Korea Bizwire)South Korean pharmaceutical firm Samsung Biologics Co. said Thursday it has signed a supply agreement with U.S.-based biotech company GreenLight Biosciences.

Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will manufacture drug substances for GreenLight’s mRNA COVID-19 vaccine candidate.

Samsung Biologics will manufacture drug substances of the mRNA COVID-19 vaccine candidate for a phase three clinical trial, officials said.

“We are delighted to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA COVID-19 vaccine candidate to better serve patients in lower income countries,” John Rim, CEO of Samsung Biologics, said in a press release.

GreenLight, which aims to provide affordable COVID-19 vaccines for the third world, aims to begin its phase one clinical trial during the first quarter of next year.

(Yonhap)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>